Order GLD Test

About GLD

Our SOLE mission is to service the dire unmet needs of our global Lyme community with a new diagnostic solution specific to Lyme Disease that is grounded in science. We created the GLD test with the goal of decreasing the number of patients being misdiagnosed.


Today the Lyme community is in desperate need of a test that works. It is well known the current two-tier diagnostic approach can be inaccurate up to fifty percent of the time as further demonstrated in Claudia Molins research with the Centers for Disease Control (CDC). While attempts have been made to increase sensitivity of the current tests, this can come at the expense of specificity.

Our Lyme community today faces 2 challenges first and foremost it needs a test that works and second the need to generate clinical awareness to get tests prescribed. The GLD test is designed to address both these important issues.


Global Lyme Diagnostics has developed a breakthrough test specifically for Lyme Disease.

After licensing technology platform and related intellectual property developed in Dr. Richard Marconi’s lab at Virginia Commonwealth University, we focused on creating a highly accurate and reproducible solution. The resulting GLD test uses our proprietary chimeritope and is designed to diagnose diverse strains of Lyme.

GLD’s test keep’s the prescribing by clinicians simple and doesn’t require any new training or equipment for the physician’s office. Our test is a simple blood draw, something the clinicians are very familiar with and don’t need to invest in training or equipment.

GLD Team

Mickey Ramchandani – CEO

As Founder and Chief Executive Officer, Mickey Ramchandani is passionate about making GLD’s mission of providing a diagnostic solution that decreases the misdiagnosis of Lyme Disease a reality.

With over 25 years of experience in the pharmaceutical and medical technology industries, Mr. Ramchandani has successfully created businesses and operating plans for large companies and startups alike. Having held key leadership positions, his expertise includes marketing, new market development and business development.

Mr. Ramchandani sets GLD’s vision and oversees its business development strategy.

Prior to Global Lyme Diagnostics, Mr. Ramchandani was GM of Baxano Surgical, a public orthopedics company. Responsibilities included regulatory, operations, sales, marketing and market development. Mr. Ramchandani also served as VP of Business Development for Baxano Surgical completing two platform deals and two product deals.

Mr. Ramchandani was previously employed as Director of Global Business Development for Kowa Research Institute. A US startup of a Japanese pharmaceutical company, Mr. Ramchandani planned and oversaw the merger of Kowa with a larger US commercial operation. Mr. Ramchandani has also been a Senior Marketing Manager and Director of New Business for Baxter International. Mr. Ramchandani started his career as a medicinal chemist doing early stage drug discovery for Pfizer, Inc.

Mr. Ramchandani has a BS in Chemistry from Campbell University, a MS in Organic Chemistry from East Carolina University and an MBA from Kenan-Flagler Business School at University of North Carolina in Chapel Hill.

Mike Luetkemeyer – CFO

As Chief Financial Officer of Global Lyme Diagnostics, Mike Luetkemeyer is responsible for leading GLD financial functions. Mr. Luetkemeyer brings extensive executive experience with publicly traded companies overseeing Investor Relations, Finance, Accounting, Corporate Planning and Development.

Prior to GLD, Mr. Luetkemeyer offered his services as an independent consultant in the areas of strategic planning, financial management and infrastructure development.

Mr. Luetkemeyer previously served as the Chief Financial Officer of TranS1, Inc., a NASDAQ-listed medical device company from April 2007 through March 2010.

Prior to serving as CFO of TranS1, Mr. Luetkemeyer served as Senior Vice President and Chief Financial Officer of Micromuse, Inc., a NASDAQ-listed provider of network management software, from October 2001 to May 2006. He also served as a member of Micromuse’s board of directors from January 2003 through February 2005, and as its interim CEO during 2003. Prior to Micromuse, Mr. Luetkemeyer also served as Chief Financial Officer at NASDAQ-listed companies Rawlings Sporting Goods and Electronic Retailing Systems.

Mr. Luetkemeyer has held a variety of senior finance positions throughout his career, including more than 10 years with General Electric, where he served with GE Aerospace, GE Semiconductor, and GE Plastics.
Mr. Luetkemeyer received his BS in Finance from Missouri State and MA in Economics from University of Missouri.

Mitchell A. Hardenbrook, M.D. – CSO

Dr. Mitchell Hardenbrook is Chief Scientific Officer (CSO) of Global Lyme Diagnostics and a board-certified spine surgeon in the Boston area. Being from a highly endemic region, Dr. Hardenbrook is very familiar with Lyme Disease. With the current limitations of Lyme diagnoses and treatment options, Dr. Hardenbrook is keenly interested in developing solutions for Lyme patients globally.

Dr. Hardenbrook specializes in muscle-sparing approaches to the cervical and lumbar spine, motion preservation, minimally invasive surgery, and use of robotics in spine surgery. A frequently-requested speaker on innovation, Dr. Hardenbrook is also an Assistant Clinical Professor at Tufts University School of Medicine, Boston, MA.

Dr. Hardenbrook completed his MD at Hahnemann University School of Medicine (1997) and served in the United States Navy, ascending to the rank of lieutenant commander. He completed his residency at the University of Maryland Medical Center Shock Trauma Center in the Department of Orthopedic Surgery, and his fellowship at New England Baptist Hospital under the Tufts University-UMass Medical Center Affiliates.

Richard Marconi, Ph.D. – Inventor

Dr. Richard T. Marconi is a Professor in the School of Medicine at Virginia Commonwealth University Medical Center and is the inventor of the Global Lyme Diagnostics platform. Dr. Marconi has 25 years of experience in the study of pathogenic spirochetes. His current research interests are diverse and include the study of molecular mechanisms of pathogenesis of Lyme disease (Borrelia burgdorferi), tick borne relapsing fever and periodontal disease.

Dr. Marconi is well recognized for his diverse research efforts and has lectured worldwide. He has served as the President of the Virginia Branch of the American Society for Microbiology, participated in over 120 national and international review panels and published more than 100 peer reviewed research articles and reviews. He has authored two definitive book chapters on Lyme disease vaccines.

The primary focus of current research in the Marconi lab is to advance human health through the development of next generation vaccines, diagnostic assays and novel therapeutic approaches for infections caused by pathogenic spirochetes and tick-borne pathogens. Dr. Marconi has demonstrated experience in product development and is among a small group of scientists that have successfully developed a vaccine. Dr. Marconi was a coinventor of an innovative vaccine for canine Lyme disease launched by Zoetis. Dr. Marconi and his research team have been working with Global Lyme Diagnostics to significantly improve diagnostics for human Lyme disease.

Dr. Marconi earned his Ph.D. at the University of Montana under Dr. Walter E. Hill where he studied the mechanisms of action of ribosome targeting antibiotics. He conducted his post‐doctoral training at The Roche Institute of Molecular Biology (Nutley, NJ) and the National Institutes of Health, Rocky Mountain Laboratories (Hamilton, MT).

At Roche, Dr. Marconi trained under Dr. Herbert Weissbach (member of the National Academy of Sciences) and Dr. Nathan Brot studying bacterial physiology. His research efforts focused on the study of the molecular regulation of methionine biosynthesis in Escherichia coli. Dr. Marconi then accepted an Intramural Research Training Award with the NIH to study the pathogenesis of Lyme disease and other spirochetal infections at Rocky Mountain Laboratories under Dr. Claude Garon.

Elizabeth Leed – Marketing Director

As Marketing Director, Elizabeth Leed is responsible for strategic marketing, branding and messaging. She is passionate about connecting with the Lyme community and sharing news of GLD’s innovative diagnostic solution.

Ms. Leed offers 10 plus years of marketing and design experience with a focus on the medical device and biotech industries. Her expertise is creating meaningful corporate and product brands while working within the confines of a regulated industry. Leed has a strong portfolio of recognizable brands and creative marketing strategies from working with both start-ups and large corporations.

Prior to GLD, Leed served as a marketing consultant for various medical device companies creating and managing brands.

Leed previously worked at Baxano Surgical rebranding the corporate identity and developing multiple product brands. She also created and managed a custom, simple-to-use sales app, with multiple user roles ensuring all compliance requirements were met.

Ms. Leed received her BFA in Communications Arts from East Carolina University School of Art.